Related Experiment Video

Updated: Jun 19, 2026

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Oral Delivery of Tocotrienols: Addressing Pharmacokinetic Challenges With Formulation-Based Strategies

An Gie Ooi1, Kah Hay Yuen2, Chee Chin Chu1

  • 1Faculty of Health and Medical Sciences, School of Pharmacy, Taylor's University, Subang Jaya, Malaysia.

Lipids
|June 18, 2026
PubMed

Insights

Tocotrienols (T3), vitamin E analogues, show therapeutic promise but suffer from poor oral bioavailability due to absorption challenges. Future formulations must combine strategies to enhance T3 absorption and efficacy.

Area of Science:

  • Pharmacology and Drug Delivery
  • Nutritional Science
  • Biochemistry

Background:

  • Tocotrienols (T3), vitamin E analogues, possess significant antioxidant and therapeutic potential.
  • Clinical applications of T3 are limited by poor and inconsistent oral bioavailability.
  • Factors contributing to low bioavailability include poor solubility, rapid elimination, instability, and limited protein binding.

Purpose of the Study:

  • To review the pharmacokinetics of tocotrienols.
  • To critically evaluate advanced oral delivery systems for improving T3 bioavailability.
  • To identify future strategies for overcoming T3 absorption barriers.

Main Methods:

  • Literature review of pharmacokinetic studies on T3.
  • Analysis of recent developments in T3 oral delivery systems.
  • Examination of intestinal absorption mechanisms, including transporter involvement (NPC1L1, SR-B1).

Main Results:

  • T3 absorption is a saturable, concentration-dependent process mediated by specific intestinal transporters.
  • Current delivery systems show some improvement in bioavailability but do not fully resolve intrinsic absorption limitations.
  • Challenges include rapid elimination, low solubility, and chemical instability.

Conclusions:

  • Overcoming T3 bioavailability issues requires integrated physicochemical and biological approaches.
  • Modulating intestinal transporters and controlling drug release kinetics are crucial for consistent absorption.
  • Next-generation T3 formulations aim for prolonged circulation and enhanced therapeutic outcomes.
Keywords:
delivery systemsoral bioavailabilityoral solid dosage formpharmacokineticstocotrienols

More Related Videos

Formulation and Characterization of Bioactive Agent Containing Nanodisks07:58

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Related Concept Videos

Drug Delivery: Overview01:16

Drug Delivery: Overview

The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the gastrointestinal...
Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Bioavailability Enhancement: Drug Permeability Enhancement01:27

Bioavailability Enhancement: Drug Permeability Enhancement

After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...